Background
By 2010, the human oxytocin literature had expanded rapidly following Kosfeld et al.’s 2005 Nature paper. MacDonald and MacDonald conducted a systematic review synthesizing the first decade of controlled intranasal oxytocin research in healthy and clinical human populations, cataloging effect sizes, moderators, and inconsistencies across the literature.
This review remains a critical reference for understanding both the promise and the context-dependence of oxytocin’s prosocial effects.
Key Findings
Trust and Social Approach:
- Intranasal oxytocin (24 IU) consistently enhanced trust-game investments in economic paradigms (multiple replications of Kosfeld 2005)
- Reduced social approach avoidance in healthy participants and in those with elevated social anxiety
- Enhanced willingness to disclose personal information in social contexts
Emotion Recognition and Theory of Mind:
- RMET performance improved in healthy volunteers (replicating Domes 2007) and preliminary data in ASD
- Oxytocin enhanced recognition of socially relevant emotional cues, particularly from faces and eyes
- Effects were strongest for ambiguous or low-intensity emotional expressions
Stress and Anxiety:
- Attenuated cortisol responses to psychosocial stressors (replicating Heinrichs 2003)
- Reduced subjective anxiety in social threat paradigms
- Protective effects were strongest when combined with social support — consistent with the “social salience” hypothesis
Important Moderators Identified:
- Sex: Oxytocin effects are more consistently positive in males; women show context-dependent and sometimes inverse effects, potentially due to estrogen-oxytocin interactions
- Baseline anxiety: Higher trait anxiety predicts stronger anxiolytic response to oxytocin in some studies
- Social context: Oxytocin appears to enhance salience of social cues broadly — increasing both positive (trust, empathy) and negative (envy, in-group favoritism) social responses depending on context
Clinical Significance
| Potential Application | Evidence Base |
|---|---|
| Autism spectrum disorder | Preliminary positive trials; large RCTs mixed |
| Social anxiety disorder | Anxiolytic effects in healthy volunteers replicated |
| PTSD social avoidance | Theoretical — HPA attenuation and trust enhancement |
| Relationship quality enhancement | Limited but suggestive data |
| Post-stroke social impairment | Emerging |
The review highlighted that oxytocin should not be viewed as a “prosocial drug” that uniformly enhances positive social function. Rather, it appears to modulate social salience — amplifying the impact of the social environment, which can be positive or negative depending on context and individual differences.
Limitations
- Publication bias likely inflated early effect size estimates; subsequent registered replications have been more mixed
- Intranasal delivery pharmacology is contested — CNS penetration may be less reliable than initially assumed
- Most studies used healthy young males; clinical populations and women are underrepresented
- Chronic or repeated dosing effects and receptor desensitization remain uncharacterized
- Effect sizes in social cognition tasks are modest (~d = 0.3–0.5); clinical significance for individual patients is uncertain